1
`
`Grun. Exh. 1053
`PGR for U.S. Patent No. 9,867,839
`
`Grün. Exh. 1015
`PGR for U.S. Patent No. 10,052,338
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2)
`furnishing of the information solicited is voluntary; and (8) the principal purpose for which the information is used by the
`U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which mayresult in termination of proceedings or abandonmentof the
`application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice to determine whether disclosure of these records is required by the
`Freedom ofInformation Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuantto the Atomic Energy Act (42 U.S.C.
`218(c)).
`A record from this system of records may bedisclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSAaspart of that agency’s
`responsibility to recommend improvements in records managementpractices and programs, under authority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of recordsfor this purpose, and any other relevant(i.e., GSA or Commerce)directive. Such
`disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may bedisclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
`wasfiled in an application which became abandonedor in which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes awareof a violation or potential violation of law or regulation.
`
`2
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`icati
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`The application data sheetis part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arrangedin a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document maybe printed and included in a paperfiled application.
`
`Secrecy Order 37 CFR 5.2
`
`Oo Portionsorall of the application associated with this Application Data Sheet mayfall under a Secrecy Order pursuantto
`
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may notbefiled electronically.)
`
`Inventor Information:
`
`
`Inventor
`Legal Name
`
`
`Prefix} Given Name
`Middle Name
`Family Name
`TepeTE
`ResidenceInformation (Select One)
`@ US Residency
`Non US Residency
`Active US Military Service
`
`|city|| State/Province [Ry|Country of Residencd
`
`Mailing Addressof Inventor:WaiingAdaressoftwvenfor——
`
`
`[Adtisst‘|feBewivanOre——OSCSC~C~“SC~“S*S*S*S*~“‘~“~S~S~S
`faddess?[P|
`roy[fervorSdSitProvince
`[PostalCode[joo——SSCSCSCSC~dSmetSS
`‘menorpT
`
`Legal Name
`
`[Prefix]GivenName|MiddleName|FamilyName|Sufix
`[EyBremelesS™~é~tSsSCO
`
`
`Residence Information (Select One) () US Residency
`@ Non US Residency
`Active US Military Service
`City
`obart TAS
`Country of Residence i
`
`
`
`
`
`Addresst|Pedals?
`
`fciy[Faas SSCSC~*~C~*diSatlProvinceTPSSCSCSC*
`[PostalGode[yuo—————S—SCSC~iRoumSSSCSCSC~*S
`All
`Inventors Must Be Listed - Additional
`Inventor Information blocks may be
`generatedwithin this form by selecting the Add button.
`
`Correspondence Information:
`
`EFS Web 2.2.12
`
`3
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Enter either Customer Number or complete the CorrespondenceInformation section below.
`For further information see 37 CFR 1.33(a).
`
`Add Email
`
`Remove Email
`
`Application Information:
`
`
`Title of the Invention
`
`OsteoclastInhibitors for Knee Conditions
`
`
`
`[_] An Addressis being provided for the correspondenceInformation of this application.
`Customer Number
`fi 5200
`Email Address
`|eCpatents@klgates.com
`
`
`
`
`Application Type [Pomowsonal
`Subject Matter py
`
`
`Total Numberof Drawing Sheets(if any) /4|SuggestedFigureforPublication(ifany)||_|
`Filing By Reference:
`
`
`Only complete this section whenfiling an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this sectionif
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information” and “Foreign Priority Information”).
`
`For the purposesofa filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previouslyfiled application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`i
`
`Application numberofthe previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`Po
`
`Publication Information:
`
`
` Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. | hereby requestthat the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months afterfiling.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a powerof attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`
`Numberwill be used for the Representative Information during processing.
`
`
`
`Please Select One:
`
`@ Customer Number
`
`US Patent Practitioner © Limited Recognition (37 CFR 11.9)
`
`Customer Number
`
`EFS Web 2.2.12
`
`4
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`Domestic Benefit/National Stage Information:
`
`
`
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365{c), or 386(c) or indicate National
`Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference
`
`
`required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`
`
`
`When referring to the current application, please leave the application number blank.
`
`
`[PriorApplicationStatus| Pending
`
`
`
`Prior Application Number|Filing Date (YYYY-MM-DD)
`
`
`
`
`
`
`
`[PriorApplicationStatus]Fabandoned [Reno
`
`
`
`
`
`
`
`
`
`
`Issue Date
`Filing Date
`Prior Application
`a
`Application
`
`Number (YYYY-MM-DD) Continuity Type Number (YYYY-MM-DD) Patent Number
`
`
`
`
`
`
`
`2014-07-29
`fu
`2015-04-14
`
`
`
`
`[PirApictenStas]Pabues Row
`
`
`
`
`
`“er
`Ria,
`[rosie |
`
`ee[peefoepenn[ieee[ome|Prior
`
`
`
`
`ApplicationStatus|Exped
`
`
`
`
`Prior Application Number
`Filing Date (YYYY-MM-DD}
`
`
`
`
`PretApplicatonStatus]Patened [Remove]
`
`
`
`
`
`
`
`a
`ER[meme Ry
`
`
`arose|Bousefamrome——_|Forwis|pas—_|porsanse
`
`
`
`Prior Application Status [Patented
`Remove
`
`
`
`Issue Date
`Filing Date
`Patent Numb
`
`
`(YYYY-MM-DD) Number|(yvYYY-MM-DD)atent
`
`
`
`2013-10-25
`2014-08-12
`
`
`
`
`Prior Application Status [Pending
`
`
`
`
`Filing Date (YYYY-MM-DD}
`Application Number
`Continuity Type
`Prior Application Number
`
`
`
`
`Fereser|Petrvatoninnatoe
`
`|_PriorApplicationStatus|Fxpred
`
`Prior Application Number|Filing Date (YYYY-MM-DD)
`
`
`
`i 3/894274
`| laims benefit of provisional
`-| 61/803721
`2013-03-20
`Prior Application Status [Bvired
`Remove
`
`
`
`EFS Web 2.2.12
`
`5
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`1958603.001 16
`Attorney Docket Number
`—
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Filing Date (YYYY-MM-DD)
`Prior Application Number
`Continuity Type
`Application Number
`2013-02-21
`| 61/767647
`| laims benefit of provisional
`i 34894274
`Remove
`Prior Application Status [Exired
`Application Number
`Continuity Type
`i 3/894274
`| laims benefit of provisional
`
`Prior Application Number
`| 61/767676
`
`Filing Date (YYYY-MM-DD)
`2013-02-21
`Remove
`
`2012-05-14 Filing Date (YYYY-MM-DD)
`
`
`
`Prior Application Number Filing Date (YYYY-MM-DD)
`
`Application Number
`Continuity Type
`
`|fisieoa274 | laims benefit of provisional | 61/764563
`
`2013-02-14
`Remove
`
`Filing Date (YYYY-MM-DD}
`2013-02-07
`
`Prior Application Number
`Continuity Type
`Application Number
`| 61/762225
`| laims benefit of provisional
`i 34894274
`Remove
`Prior Application Status [Exred
`
`Application Number
`Continuity Type
`i 3/894274
`| laims benefit of provisional
`
`Prior Application Number
`| 61/655541
`
`Filing Date (YYYY-MM-DD)
`2012-06-05
`
`Remove
`
`Application Number
`i 3/894274
`
`Continuity Type
`| laims benefit of provisional
`
`Application Number
`i 3/894274
`
`Continuity Type
`| laims benefit of provisional
`
`Prior Application Number Filing Date (YYYY-MM-DD)
`
`>| 61/655527
`2012-06-05
`
`
`Filing Date (YYYY-MM-DD}
`Prior Application Number
`| 61/654383
`2012-06-01
`Remove
`
`Remove
`
`Application Number
`i 3/894274
`
`Continuity Type
`| laims benefit of provisional
`
`Prior Application Number Filing Date (YYYY-MM-DD)
`
`| 61/654292
`2012-06-01
`
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
` i 3/894274 | laims benefit of provisional | 61/647478 2012-05-15
`
`
`
`Prior Application Number
`Continuity Type
`Application Number
`| 61/646538
`| laims benefit of provisional
`i 34894274
`Additional Domestic Benefit/National Stage Data may be generated within this form
`
`by selecting the Add button.
`
`Foreign Priority Information:
`
`EFS Web 2.2.12
`
`6
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`—
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)! the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g){1).
`
`Remove
`
`Application Number
`
`Filing Date (YYYY-MM-DD)
`
`Access Code! (if applicable)
`
`
`
`Addbutton.
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`
`
`
`
`
`
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`
`16, 2013, will be examined underthefirst inventorto file provisions of the AIA.
`
`Authorization to Permit Access:
`
`[_] Authorization to Permit Access to the Instant Application by the Participating Offices
`
`EFS Web 2.2.12
`
`7
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any otherintellectual property offices in which a foreign application claiming priority to the instant patent application
`is filled access to the instant patent application. See 37 CFR 1.14{c) and (h). This box should not be checkedif the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or otherintellectual property office in which a foreign application claiming priority
`to the instant patent applicationis filed to have accessto the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), accesswill be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claimspriority under 35 U.S.C. 119{a)-{d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has beenfiled in the instant patent application; and 3) any U_S. application-as-filed from which benefit is
`soughtin the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date offiling this Authorization.
`
`
`
`Fax Number
`
`Applicant Information:
`
`Providing assignmentinformation in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`Applicant
`ff
`If the applicantis the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`Theinformation to be provided in this section is the name and addressof the legal representative whois the applicant under 37 CFR
`1.43; or the name and addressof the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise showssufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventoris obligated to assign, or person who otherwise showssufficient
`proprietary interest) together with one or morejoint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`Clear
`
`
`Joint Inventor
`Legal Representative under 35 U.S.C. 117
`@ Assignee
`
`
`Person to whom theinventoris obligated to assign.
`
`Person who showssufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Nameof the Deceased or Legally Incapacitated Inventor :
`
`If the Applicant is an Organization check here.
`xX
`
`
`
`
`Mailing Address Information For Applicant:
`
`fAddesst|a|State/Province
`
`
`
`
`
`Postal Code
`
`Phone Number
`
`EFS Web 2.2.12
`
`8
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`
`
`Add
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`
`Assignee Information including Non-Applicant Assignee Information:
`
`
`Providing assignment information in this section does not subsitute for compliance with any requirementof part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`
`
`Assignee ,
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assigneeis also desired on the
`patent application publication.
`
`
`
`LC]
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`
`Prefix
`
`Family Name
`
`Suffix
`
`Given Name
`
`Middle Name
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`Address 1
`
`Address 2
`
`State/Province
`
`
`
`
`
`
`
`Phone Number
`
`Fax Number
`
`
`
`Postal Code
`
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications.
`
`
`
`|Signature BrentA. Johnson/ | Date (YYYY-MM-DD) |pos-12.1
`
`
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`Add
`
`EFS Web 2.2.12
`
`9
`
`

`

`PTO/AIA/14 (07-14)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Osteoclast Inhibitors for Knee Conditions
`
`Attorney Docket Number|1958603.001 16
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`This collection of information is required by 3 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upontheindividual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.12
`
`10
`
`10
`
`

`

`Privacy Act Statement
`
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(\(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Departmentof Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`2.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`A recordin this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, whenthe individual has requested assistance from the Memberwith respect to the subject matter of
`the record.
`
`A recordin this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent C o o p eration Treaty.
`
`A recordin this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)}).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSAaspart of that agency's responsibility to recommend improvements in records
`managementpractices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i-e., GSA or Commerce)directive. Such
`disclosure shall not be used to make determinations aboutindividuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuan
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned orin which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency,if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`EFS Web 2.2.12
`
`11
`
`11
`
`

`

`
`
`PTOIALAION (06-12)
`Approved for use through 04/31/2014, OMB 0551-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no sersars are required to respond to @ collection of information uniess f displays a vaild OMB contro! number.
`
`i
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.76}
`
`Titeof|OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS
`nvention
`
`en previously filed. Use an additional PTO/AIA/O1 formfor each additional inventor, This coflection of information is required by 35 U.S.C. 115 and 3? CFR 1.83. The information {s required to obtain ar retain a benefit by ihe public whichis to file (and
`
`f
`Patitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may
`coriribute to identily theil. Personal infomation such as social security numbers, bank account numbers, or credit card numbers |
`{ather than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO}
`to support a petition or an application.
`if this type of personal information is Included in documents submitted to the USPTO,
`5
`petitioners/applicants should consider redacting such personal information from the documents before submitting them io the
`USPTO. Pelitioner/applicant is advised that the recard of a patent application is available to the public after publication of the
`application (unless a non-publication request in compliance with 37 CFR 1.213{a) is made in the application) or issuance of a
`‘patent. Furthermore, the record from an abandonedapplicationmay also be available to the public ifthe application is
`referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and creditcard authorization forms
`TO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.
`
`| As the below named inventor, | hereby declare that:
`
`This declaration
`is directed to:
`
`I
`
`[gl
`ei
`[|
`
`+.
`‘
`;
`The atlached application, or
`United States agplication or PCTinternational application number
`filed on
`
`The above-identified application was made or authorized to be made by me.
`
`| believe that | am the original inventor or an Griginal joint inventor of a claimed invention in the appiication.
`
`i hereby acknowledge that any willful false staternent made in this declaration is punishable under 18 U.S.C. 1001
`by fine or imprisonment of not more than five (5) years, or both.
`
`WARNING:
`
`LEGAL NAME OF INVENTOR
`
`Inventor
`
`Signature:
`
`Herriot Tabuteau
`
`/Herriot Tabuteau/
`
`Date (Optional:
`
`‘icte: An application data sheet (PTO/S8/14 or equivalent), including naming the entire inventive entity, must accompanythis form or must have
`
`is governed by 35 U.S.C. 122 and 37 CFR 1.14 and 1.14. This collection is estimated to take t minute to
`by the USPTO to process) an application. Confidentiality
`
`complete, including gathering, preparing, and subrnitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any
`
`
`comments on the amount of time you require to complete this form and/or suggestionsfor reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Gox 1450, Alexandria, VA 22313-1456. DO NOT SEND FEES OR COMPLETED FORMS TO
`THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22343-1460,
`ffyou need assistance in completing the form, call 1-800-PTO-9799 and select option 2
`
`12
`
`12
`
`

`

`PTOUAIIBL 81H
`Approved for use MhmughOU/S1/2014.. OMS C6St-O0S2
`US. DEPARTMENT OF COMMERCE
`U.S: Patent and Yrademark Office:
`Underthe Pagerank Reduction Atot TOSS, ne péisons ans requirest$5 iespond tea collention af idormation unless Realaptayea Valid OMB control nbsribes.
`DECLARATION (37 GER 4.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET(87 CFR 1.78}
`| OST:EOCLAST INHIBITORS FOR KNEE CONDITIONS
`
`| invention |
`
`\
`“Tite of
`
`i As thebelow named inventor, | hereby declarethat
`Ths declaration
`Js directed fa’ The attached application,‘or
`i] United States application or POT international application nuraber
`filed or
`
`f The alicve-identiied appication was meds or authorized to be made by:me.
`
`Et beliave that lamihe original inventor-or anh origiial joint iventor of a claiméd invention in the-application
`
`} hereby acknowledge chat any will false statement made.in this deniaration iepunishable tinder 16 W.8:C. 1007
`:
`Lby fine-or imprisonment of not more than five (5) yeurs, or both.
`
`WARNING:
`(otherthor:a.eWeckor opal card authentzation form PTO2838 dubinited for payment purposes)|Is newer roquired|by theUSPTO!
`io support a pelifion or.an application.
`ifthis tyne of persénal.information is included in-documents subraitied tothe USPTO,
`patitioners/appiicanis should consider redacting such personal inforraation fromthe documents. before submitting them to.the
`USPTO. Peliionerfapplicant|ig advised that the record of a patent application is avaliable te the oublicafter publication ofthe
`appligation (unless a non-publication request in compliance with 9? CPR 7.213{a)is madein the application} or issuance. of a
`patent. Furtheimore, ine record from an abandoned application may also be available to the publicifthe application is
`referenced: ine:publishsdapplicationoran lesuad patent (see 37 CER 114). Checks and credit carl authorization forms
`PTO-2038 aubmitied for payment purposes are not retained in the application file end therefore are not publicly avaliable,
`
`‘been previously fad: Use an addtional PTOAMANT forn for each additonal:inventor:
`
`LEGAL NAME OF INVENTOR
`
`invenice, GraemeJones.
`Signature:
`
`a ate (Optional)STAYee
`
`i NotesAn application datz: sheet rrCVSAN4 of equivalent},including naming ihe -antike inventive entity, musl aecompanythis form oFmustnave
`
`“The Coke a infornedion:ig. regured y38 US.18 ad 37 CFR 4.83. Theinformation ta required40 htake orzetaina benefit by the public which is fo file(and
`bythe USPTOt process) anappiication, Contdentiaiiy is govemed by 45 U.S.C. 122 and 3